Home / Annual Review 2019 – 2020 / Managing risk / CMS advises Zentiva on its acquisition of Alvogen
  1. Facing the future
    1. Advising on a EUR 1.1bn Bulgarian gas pipeline procurement
    2. Ukrainian Gas Transmission System unbundling
    3. ALPLA expands its global plastic recycling capabilities
    4. Selling the Merkur offshore wind farm
    5. The green economy: identifying primary risks and key opportunities
    6. Solving global challenges
  2. Navigating a changing world
    1. CMS advises on major East Africa paint transaction
    2. Helping Teyliom Hospitality’s expansion in Central and West Africa
    3. Data and risk: challenges in an uncertain world
    4. Working through the COVID-19 lockdown
    5. Commerz Real lands the largest deal in its history
    6. Shaping the new normal
  3. Harnessing technology
    1. MultiChoice separates from Naspers and lists on JSE
    2. CMS advises on first ever European real estate transaction using blockchain
    3. Technology: a unifying force
    4. Smart living: creating a framework for disruption and innovation
    5. CMS helps Korean investors acquire prime real estate assets
    6. CymbiQ Group on expansion course
    7. Online gambling grows as Gamesys is sold to JPJ Group
    8. CMS helps the BBC launch the streaming service BritBox in the UK
    9. Lupl delivers transformative open industry platform for legal matters
    10. CMS advises on ‘Train Maya’ rail project
  4. Managing risk
    1. ST Pharm establishes new medical testing and analysis business line
    2. CMS advises Blackstone on its investment in Carrix
    3. Colgate-Palmolive acquires premium anti-ageing skin care brand
    4. CMS advises Zentiva on its acquisition of Alvogen
    5. The true cost of ESG
  5. Inside CMS
    1. CMS Academy adds participants through digital learning
  6. CSR and Diversity & Inclusion
    1. Diversity and Inclusion at CMS UK
    2. Médecins Sans Frontières (MSF): CMS Charity Partner
  7. Interviews
    1. Interview with Gabriela Staber
    2. Interview with Sophie Marquet
    3. Interview with Courtney Rothery
    4. Interview with María González Gordon
    5. Interview with Mariel Dimsey
    6. Interview with Nedžida Salihović-Whalen
    7. Interview with Annemieke Hazelhoff
    8. Interview with Michelle Barclay
    9. Interview with Deepa Vallabh
    10. Interview with Gerlind Wisskirchen

CMS advises Zentiva on its acquisition of Alvogen

By acquiring the Alvogen portfolio, Zentiva has cemented its position as a true generic pharmaceutical leader in the region. The combined brands have a strong name and long history across the markets in the region.
Helen Rodwell

Zentiva, a pan-European pharmaceutical company, acquired the CEE business of Alvogen, a global generic and over-the-counter (OTC) drug manufacturer in October 2019. The Alvogen deal is one of the headline transactions in CEE in 2019 and brings together two regional leaders in generics and OTC pharmaceuticals.

A cross-border CMS team advised Zentiva on the transaction. The team was led by Helen Rodwell, Managing Partner of CMS in Prague. She was supported by colleagues from Bulgaria, the Czech Republic, Hungary, the Netherlands, Poland, Romania, Russia and UK. 

By acquiring the Alvogen portfolio, Zentiva has cemented its position as a true generic pharmaceutical leader in the region. The combined brands have a strong name and long history across the markets in the region,” said Helen Rodwell.

Zentiva, which has flagship sites in Prague and Bucharest, is a portfolio company of Advent International. CMS had previously assisted Advent with its EUR 1.9bn acquisition of Zentiva from Sanofi in 2018. 

Alvogen’s business in CEE covers 14 jurisdictions in the region, including Balkan markets, Bulgaria, Hungary, Poland, Romania and Russia. Its brands include Lactacyd, Persen and EuBiotic.